In vivo and in vitro study of several pharmacodynamic effects of meropenem

Scandinavian Journal of Infectious Diseases
F FuentesJ Prieto

Abstract

Several pharmacodynamic parameters are being studied and applied to the design of dosage regimens. The thigh infection model in neutropenic mice has been used in this study to investigate the in vivo postantibiotic effect (PAE) of meropenem against S. aureus, E. coli and P. aeruginosa. The sub-minimum inhibitory concentration (sub-MIC) postantibiotic effect (PA SME) of 1/2, 1/4 and 1/8 x MIC was also determined in vitro on S. aureus and E. coli after pre-exposure of these microorganisms to 10 x MIC of meropenem. The in vitro PAE was also determined. In vivo killing curves using 2 different short dosage regimens were also studied to relate the lethal effect to the time that serum levels were above the MIC. No significant in vivo and in vitro PAEs were observed. The PA SMEs were higher for S. aureus than for E. coli. The 2 short dosage regimens, in vivo, were equally effective in killing S. aureus, but not E. coli. These results suggest that the pharmacodynamics of meropenem on Gram-negative strains may need further study to elucidate the mechanisms and characteristics of these parameters. On the other hand, we need to standardize a reliable in vitro method to monitor regrowth with a good correlation with the in vivo conditions.

References

Sep 1, 1992·Antimicrobial Agents and Chemotherapy·I Odenholt-TornqvistO Cars
May 1, 1991·The Journal of Antimicrobial Chemotherapy·W A CraigS C Ebert
Sep 1, 1991·Antimicrobial Agents and Chemotherapy·I Odenholt-TornqvistO Cars
Sep 1, 1991·Antimicrobial Agents and Chemotherapy·U FlückigerA U Gerber
Oct 1, 1990·The Journal of Antimicrobial Chemotherapy·P A Majcherczyk, D M Livermore
Feb 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I OdenholtO Cars
Sep 1, 1989·The Journal of Antimicrobial Chemotherapy·H L NadlerW Sheikh
Oct 1, 1989·Antimicrobial Agents and Chemotherapy·J Renneberg, M Walder
Aug 1, 1989·The Journal of Antimicrobial Chemotherapy·I OdenholtO Cars
Oct 1, 1988·The Journal of Infectious Diseases·B VogelmanW A Craig
Dec 1, 1986·The Journal of Antimicrobial Chemotherapy·S GudmundssonW A Craig
Nov 1, 1984·Antimicrobial Agents and Chemotherapy·C I BustamanteH C Standiford
Nov 1, 1994·Antimicrobial Agents and Chemotherapy·F M MacKenzieD Jason
Dec 1, 1993·The Journal of Antimicrobial Chemotherapy·M M Martín CamineroJ Prieto Prieto
Oct 1, 1993·The Journal of Antimicrobial Chemotherapy·F M MacKenzie, I M Gould
Jun 1, 1993·The Journal of Antimicrobial Chemotherapy·I Odenholt-Tornqvist

❮ Previous
Next ❯

Citations

Jun 29, 2013·Clinical Pharmacokinetics·Tiphaine Goulenok, Bruno Fantin
Jan 4, 2001·International Journal of Antimicrobial Agents·I Odenholt
Feb 23, 2012·Antimicrobial Agents and Chemotherapy·Wang HengzhuangNiels Høiby
Nov 13, 2004·Intensive Care Medicine·Rina MehrotraMark Palazzo
Aug 26, 2006·Diagnostic Microbiology and Infectious Disease·Christine T OngDavid P Nicolau
Jul 15, 2016·Clinical Microbiology Reviews·Mordechai GrupperDavid P Nicolau
Feb 3, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A NyhlénI Nilsson-Ehle
Aug 2, 2018·Veterinary Surgery : VS·Robin L FontenotCathleen A Mochal-King

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
I OdenholtO Cars
The Journal of Antimicrobial Chemotherapy
M A ShapiroS R VanderRoest
European Journal of Clinical Microbiology
A KümmelF D Daschner
© 2021 Meta ULC. All rights reserved